





FIG. 1



ALT, alanine aminotransferase; AST, aspartate aminotransferase; LFTs, liver function tests.

FIG. 2





FIG. 3

grace STUDY

A phase 3, double-blind, randomized-withdrawal study to assess the efficacy and safety of relacorilant in patients with endogenous hypercortisolism of all etiologies




For treatment responders:

- Start of randomized withdrawal phase
- Subjects receive either relacorilant or placebo (1:1 randomization)

GRADIENT STUDY

The first phase 3, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of relacorilant in patients with cortisol-secreting adrenal adenoma(s) or adrenal hyperplasia



Adrenocortical Cancer STUDY

A phase 1b study to evaluate the safety and efficacy of relacorilant in combination with pembrolizumab in patients with metastatic adrenocortical carcinoma associated with hypercortisolism




FIG. 4